Curocell
Curocell is a biotech company in Daejeon, South Korea, founded in 2017.
큐로셀 - 혁신적인 항암면역세포치료제 개발의 선두주자
- Headquarters
- Daejeon
- Employees
- 51–200
- Founded
- 2017
- Business Model
- B2B
- Website
- curocellbtx.com
About
Curocell is a clinical-stage biotechnology company headquartered in Daejeon, South Korea, pioneering the development of next-generation CAR-T cell therapies for hematologic malignancies. Founded in 2017, Curocell is Korea's first company to obtain regulatory approval to conduct CAR-T clinical trials, and received MFDS approval for its lead product anbal-cel (Rimqarto) in 2026, making it the first domestically developed CAR-T therapy in South Korea. The company uses genetically engineered immune cells to develop innovative anti-cancer immunotherapy treatments and manufactures its advanced biologics in a state-of-the-art GMP facility.
Summary
It lists 51–200 employees.
Tech & App Stack
2 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/curocell"><img src="https://indexed.vc/api/badge/company/curocell" alt="Curocell on Indexed.vc" width="260" height="76" /></a>